Eisai announced that the FDA has approved Aciphex Sprinkle (rabeprazole sodium) Delayed-Release Capsules for the treatment of gastroesophageal reflux disease (GERD) in children 1–11 years of age for ...

In February, the indications for Aciphex were expanded to include the treatment of patients with symptomatic gastroesophageal reflux disease GERD. Aciphex, a proton pump inhibitor, can now be used for ...

March 13, 2007 — The US Food and Drug Administration (FDA) has approved first-time generic formulations for rabeprazole sodium 20-mg delayed-release tablets and ranitidine HCl 15-mg/mL oral ...

Eisai announced that Aciphex Sprinkle (rabeprazole sodium) Delayed-Release Capsules are now available for the treatment of gastroesophageal reflux disease (GERD) in children 1–11 years old for up to ...

Aciphex - the liver, normalizing acidity of a stomach, see of a small pomp. It is seen at gastroduodenal ulcer in the circulation phase, gastroesophageal reflux disease; feelings which are gathered by ...

HealthDay News — The FDA has approved the first generic versions of the gastroesophageal reflux disease (GERD) drug Aciphex (rabeprazole sodium) for people aged 12 and older, the agency has announced.

WOODCLIFF LAKE, N.J., Nov. 30, 2012 /PRNewswire/ -- Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review Eisai's New Drug Application (NDA) for ...

(HealthDay)—The first generic versions of the anti-GERD drug Aciphex (rabeprazole sodium) have been approved by the U.S. Food and Drug Administration for people aged 12 and older, the agency said ...

WOODCLIFF LAKE, N.J. The Food and Drug Administration has approved Aciphex for treatment of gastroesophageal reflux disease in adolescents age 12 and older, Tokyo-based Eisai’s North America ...

Japan’s Eisai says that US regulators have granted a priority review for a new application of the firm’s proton pump inhibitor Aciphex. Japan’s Eisai says that US regulators have granted a priority ...

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced today that the company has decided to terminate development of its investigational proton pump inhibitor (PPI), ...